MOUNTAIN VIEW, Calif., Aug. 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the second quarter ended June 30, 2008.
The net loss for the second quarter ended June 30, 2008 was $16.5
million compared with $8.7 million during the same period in 2007. The net
loss for the first six months of 2008 was $30.8 million compared to $15.3
million for the first six months of 2007. As of June 30, 2008, MAP
Pharmaceuticals had cash, cash equivalents and short-term investments of
2008 Year-to-date accomplishments
-- Clinical development
-- Initiated a Phase 3 clinical program to evaluate UDB for the
potential treatment of pediatric asthma.
-- Initiated a Phase 3 clinical program to evaluate MAP0004 for the
potential treatment of migraine, pursuant to a Special Protocol
Assessment with the U.S. Food and Drug Administration.
-- Announced positive results from a pharmacokinetic clinical trial
of UDB, demonstrating lower systemic drug exposure when compared
to the currently marketed conventional nebulized budesonide.
-- Demonstrated positive results from a Phase 2a clinical study
evaluating MAP0005 for the potential treatment of asthma and
chronic obstructive pulmonary disease (COPD).
-- Peer-reviewed presentations
-- Published positive results from a Phase 2 study evaluating the
safety, tolerability and pharmacokinetics of MAP0004 in adult
asthmatics in Current Medical Research and Opinion.
-- Published positive results from a Phase 1 study evaluating the'/>"/>
|SOURCE MAP Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved